{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:41:03Z","timestamp":1773294063057,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT 1109330"],"award-info":[{"award-number":["GNT 1109330"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT 1128343"],"award-info":[{"award-number":["GNT 1128343"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>To evaluate the safety and efficacy of a treat-and-extend protocol of aflibercept for cystoid macular oedema (CMO) secondary to central retinal vein occlusion (CRVO).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Twenty patients with CMO secondary to CRVO were included in this prospective cohort study. After 3 loading 4-weekly injections, treatment intervals were increased by 2\u2009weeks if there was no clinical activity, to a maximum of 12\u2009weeks. If clinical activity recurred or persisted, the interval between injections was shortened by 2\u2009weeks, to a minimum of 4\u2009weeks. Main outcome measures were change in visual acuity and the proportion of patients gaining 15 or more Early Treatment of Diabetic Retinopathy Study (ETDRS) letters from baseline at 6, 12 and 18\u2009months.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Mean BCVA gain from baseline was 19.7\u2009\u00b1\u200913.8, 22.2\u2009\u00b1\u200913.9 and 21.9\u2009\u00b1\u200915.8 ETDRS letters at 6, 12 and 18\u2009months, respectively. Sixty-five percent of patients gained 15 or more ETDRS letters at 6\u2009months, increasing to 70.6% at 12 and 18\u2009months. Patients received 5.0 [4.0 to 6.0], 8.5 [8.0 to 10.3] and 11.0 [9.0 to 12.5] injections by 6, 12 and 18\u2009months, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The visual outcomes achieved with a treat-and-extend protocol in this study were similar to the pivotal trials of aflibercept for CMO secondary to CRVO, which used monthly and then as-needed protocols.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Australian and New Zealand Clinical Trials Registry, registration number ACTR<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=368379&amp;isReview=true\">N12615000417583<\/jats:ext-link>, 01\/05\/2015.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-020-01346-8","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T08:05:47Z","timestamp":1582531547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion \u2013 an 18-month prospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Roderick","family":"O\u2019Day","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndell L.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhpal","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeewa","family":"Wickremasinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"1346_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ophtha.2010.04.019","volume":"118","author":"SS Hayreh","year":"2011","unstructured":"Hayreh SS, Podhajsky PA, Zimmerman MB. Natural History of Visual Outcome in Central Retinal Vein Occlusion. Ophthalmology. 2011;118:119\u201333.e2.","journal-title":"Ophthalmology"},{"key":"1346_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","volume":"117","author":"RL McIntosh","year":"2010","unstructured":"McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113\u201323.e15.","journal-title":"Ophthalmology"},{"key":"1346_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","volume":"155","author":"DM Brown","year":"2013","unstructured":"Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155:429\u201337.e7.","journal-title":"Am J Ophthalmol"},{"key":"1346_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124\u201333.e1.","journal-title":"Ophthalmology"},{"key":"1346_CR5","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041\u20139.","journal-title":"Ophthalmology"},{"key":"1346_CR6","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","volume":"121","author":"JS Heier","year":"2014","unstructured":"Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121:1414\u201320.e1.","journal-title":"Ophthalmology"},{"key":"1346_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","volume":"121","author":"J-F Korobelnik","year":"2014","unstructured":"Korobelnik J-F, Holz FG, Roider J, et al. Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121:202\u20138.","journal-title":"Ophthalmology."},{"key":"1346_CR8","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","volume":"158","author":"Y Ogura","year":"2014","unstructured":"Ogura Y, Roider J, Korobelnik J-F, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158:1032\u20138.","journal-title":"Am J Ophthalmol"},{"key":"1346_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802\u20139.","journal-title":"Ophthalmology."},{"key":"1346_CR10","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","volume":"119","author":"D Boyer","year":"2012","unstructured":"Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024\u201332.","journal-title":"Ophthalmology."},{"key":"1346_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","volume":"97","author":"FG Holz","year":"2013","unstructured":"Holz FG, Roider J, Ogura Y, et al. VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97:278\u201384.","journal-title":"Br J Ophthalmol"},{"key":"1346_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamaophthalmol.2017.6843","volume":"136","author":"IU Scott","year":"2018","unstructured":"Scott IU, VanVeldhuisen PC, Ip MS, et al. Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: secondary outcomes from the SCORE2 randomized clinical trial. JAMA Ophthalmol. 2018;136:337\u201345.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"1346_CR13","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/IAE.0000000000002171","volume":"39","author":"Manuel Casselholm de Salles","year":"2019","unstructured":"Casselholm de Salles M, Amr\u00e9n U, Kvanta A, Epstein DL. Injection frequency of aflibercept versus ranibizumab in a treat-and-extend regimen for central retinal vein occlusion: A Randomized Clinical Trial. Retina 2019;39:1370\u20136. https:\/\/doi.org\/10.1097\/IAE.0000000000002171.","journal-title":"Retina"},{"key":"1346_CR14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/IAE.0000000000001782","volume":"38","author":"A Lotfy","year":"2018","unstructured":"Lotfy A, Solaiman KAM, Abdelrahman A, Samir A. Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina Phila Pa. 2018;38:1795\u2013800.","journal-title":"Retina Phila Pa"},{"key":"1346_CR15","first-page":"27","volume":"239","author":"R Osaka","year":"2018","unstructured":"Osaka R, Muraoka Y, Miwa Y, et al. Anti-vascular endothelial growth factor therapy for macular edema following central retinal vein occlusion: 1 initial injection versus 3 monthly injections. Int J Ophthalmol Z Augenheilkd. 2018;239:27\u201335.","journal-title":"Int J Ophthalmol Z Augenheilkd"},{"key":"1346_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","volume":"123","author":"M Larsen","year":"2016","unstructured":"Larsen M, Waldstein SM, Boscia F, et al. Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology. 2016;123:1101\u201311.","journal-title":"Ophthalmology."},{"key":"1346_CR17","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1097\/IAE.0000000000000134","volume":"34","author":"F Abedi","year":"2014","unstructured":"Abedi F, Wickremasinghe S, Islam AFM, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina Phila Pa. 2014;34:1531\u20138.","journal-title":"Retina Phila Pa"},{"key":"1346_CR18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","volume":"122","author":"JJ Arnold","year":"2015","unstructured":"Arnold JJ, Campain A, Barthelmes D, et al. Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122:1212\u20139.","journal-title":"Ophthalmology."},{"key":"1346_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1442-9071.1996.tb01585.x","volume":"24","author":"AP Luckie","year":"1996","unstructured":"Luckie AP, Wroblewski JJ, Bird AC, et al. The venous closing pressure in central retinal vein obstruction. Aust N Z J Ophthalmol. 1996;24:233\u20138.","journal-title":"Aust N Z J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01346-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-020-01346-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01346-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:20:24Z","timestamp":1614039624000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01346-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01346-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"14 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was adherent to the tenets of the Declaration of Helsinki, and was approved by the ethics committee of the Royal Victorian Eye and Ear Hospital, Melbourne. Written informed consents were obtained from all patients participating in the trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}